Head-to-head · free

Quest Diagnostics vs Dianthus Therapeutics, Inc.

DGX vs DNTH — return on capital, cash generation, margins and balance sheet side by side.

DGX

5 / 6

measures where DGX leads

DNTH

1 / 6

measures where DNTH leads

A simple count of which company scores better on each measure — not a recommendation to buy or sell.

MeasureDGX · FY2025DNTH · FY2025
Revenue$11.0B$2.0M
Net income$992.0M(162.3M)
Revenue growth (yearly, multi-year)0.6%-67.3%
Free cash flow$1.4B—
Free cash flow margin12.3%—
Net cash / (debt)——
ROIC8.5%—
Return on equity14.2%-38.4%
Gross margin33.2%—
Operating margin14.1%-8739.3%
Net debt / EBITDA2.57x0.29x

Figures are as reported by each company; latest fiscal year shown.

Where Quest Diagnostics's cash went (FY2025)

Capital spending
$527.0M
Buybacks
—
Dividends
—
Acquisitions
—
Net debt issued / (repaid)
—
Full DGX profile →

Where Dianthus Therapeutics, Inc.'s cash went (FY2025)

Capital spending
—
Buybacks
—
Dividends
—
Acquisitions
—
Net debt issued / (repaid)
—
Full DNTH profile →

Ask which business is stronger

"Which one reinvests at higher returns?" "Who carries more risk in its filings?" Get answers drawn straight from both companies' filings.

Compare them free

More comparisons